{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:04:14Z","timestamp":1792569854455,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejim.2025.07.028","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T02:53:24Z","timestamp":1753584804000},"page":"106432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Crystal clear \u2013 part I: The role of uric acid in cardiorenal disease"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-0042","authenticated-orcid":false,"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo FG","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0001","doi-asserted-by":"crossref","first-page":"63","DOI":"10.11613\/BM.2012.007","article-title":"Uric acid as one of the important factors in multifactorial disorders\u2013facts and controversies","volume":"22","author":"Pasalic","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1016\/j.ejim.2025.07.028_bib0002","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2015.08.109","article-title":"Regulation of uric acid metabolism and excretion","volume":"213","author":"Maiuolo","year":"2016","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0003","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.ejim.2025.07.028_bib0004","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.3390\/ijms24087027","article-title":"Purine metabolism dysfunctions: experimental methods of detection and diagnostic potential","volume":"24","author":"Cicero","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.ejim.2025.07.028_bib0005","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/1440-1681.13539","article-title":"An update of genetics, co-morbidities and management of hyperuricaemia","volume":"48","author":"Zhu","year":"2021","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.028_bib0006","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","article-title":"The crystallization of monosodium urate","volume":"16","author":"Martillo","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"10.1016\/j.ejim.2025.07.028_bib0007","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1096\/fasebj.6.8.1592211","article-title":"Antibodies against crystals","volume":"6","author":"Kam","year":"1992","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"Wu","year":"1992","journal-title":"J Mol Evol"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0009","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mehy.2008.01.017","article-title":"The planetary biology of ascorbate and uric acid and their relationship with the epidemic of obesity and cardiovascular disease","volume":"71","author":"Johnson","year":"2008","journal-title":"Med Hypotheses"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/jhev.1997.0184","article-title":"Hominoid evolution and environmental change in the Neogene of Europe: a European Science Foundation network","volume":"34","author":"Agust\u00ed","year":"1998","journal-title":"J Hum Evol"},{"key":"#cr-split#-10.1016\/j.ejim.2025.07.028_bib0011.1","unstructured":"Johnson R.J., Andrews P., Benner S.A., Oliver W. Theodore E. Woodward award. The evolution of obesity: insights from the mid-miocene. Trans Am Clin Climatol Assoc. 2010;121:295-305"},{"key":"#cr-split#-10.1016\/j.ejim.2025.07.028_bib0011.2","unstructured":"discussion 305-8. Erratum in: Trans Am Clin Climatol Assoc. 2013;124:294."},{"issue":"5","key":"10.1016\/j.ejim.2025.07.028_bib0012","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jare.2017.03.003","article-title":"Physiological functions and pathogenic potential of uric acid: a review","volume":"8","author":"El Ridi","year":"2017","journal-title":"J Adv Res"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.028_bib0013","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1253\/circj.CJ-14-1267","article-title":"Depletion of uric acid due to SLC22A12 (URAT1) loss-of-function mutation causes endothelial dysfunction in hypouricemia","volume":"79","author":"Sugihara","year":"2015","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12576-023-00894-0","article-title":"Identification of three distinct cell populations for urate excretion in human kidneys","volume":"74","author":"Sakaguchi","year":"2024","journal-title":"J Physiol Sci"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.028_bib0015","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00011-024-01863-y","article-title":"The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target","volume":"73","author":"Alabarse","year":"2024","journal-title":"Inflamm Res"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0016","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s12013-024-01512-5","article-title":"Hyperuricemia facilitates Uric acid-mediated vascular endothelial cell damage by inhibiting mitophagy","volume":"83","author":"Wu","year":"2025","journal-title":"Cell Biochem Biophys"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s42358-023-00307-1","article-title":"Comparison of the different monosodium urate crystals in the preparation process and pro-inflammation","volume":"63","author":"Yan","year":"2023","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.ejim.2025.07.028_bib0018","article-title":"The fifth element: is vascular dysfunction an intrinsic feature of gout?","volume":"72S","author":"Pillinger","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ejim.2025.07.028_bib0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/TCRM.S232033","article-title":"Uric acid and arterial stiffness","volume":"16","author":"Albu","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.028_bib0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000028589.66335.AA","article-title":"Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity","volume":"40","author":"Watanabe","year":"2002","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00424-021-02606-2","article-title":"Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection","volume":"474","author":"Bahadoran","year":"2022","journal-title":"Pflugers Arch"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.028_bib0022","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.3390\/biomedicines10123067","article-title":"Hyperuricemia and endothelial function: is it a simple association or do gender differences play a role in this binomial?","volume":"10","author":"Ciarambino","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0023","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/0115734021277772240124075120","article-title":"Xanthine oxidoreductase in the pathogenesis of endothelial dysfunction: an update","volume":"20","author":"Mudgal","year":"2024","journal-title":"Curr Hypertens Rev"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0024","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/ijms23010531","article-title":"Impact of uremic toxins on endothelial dysfunction in chronic kidney disease: a systematic review","volume":"23","author":"Harlacher","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.028_bib0025","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41440-022-01116-7","article-title":"Excited UA study investigators. Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia","volume":"46","author":"Naganuma","year":"2023","journal-title":"Hypertens Res"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.028_bib0026","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/metabo14110642","article-title":"Influence of uric acid on vascular and cognitive functions: evidence for an ambivalent relationship","volume":"14","author":"Baratta","year":"2024","journal-title":"Metabolites"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.028_bib0027","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3390\/ijms25031888","article-title":"Immunological profile and markers of endothelial dysfunction in elderly patients with cognitive impairments","volume":"25","author":"Goncharov","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.028_bib0028","doi-asserted-by":"crossref","first-page":"e0300","DOI":"10.1097\/XCE.0000000000000300","article-title":"Progress of uric acid in cardiovascular disease","volume":"13","author":"Gan","year":"2024","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0029","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1515\/cclm-2015-0523","article-title":"Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis","volume":"54","author":"Braga","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.028_bib0030","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5603\/CJ.2018.0116","article-title":"Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk","volume":"25","author":"Borghi","year":"2018","journal-title":"Cardiol J"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.028_bib0031","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1371\/journal.pmed.0020076","article-title":"Serum uric acid and coronary heart disease in 9458 incident cases and 155,084 controls: prospective study and meta-analysis","volume":"2","author":"Wheeler","year":"2005","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.028_bib0032","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/acr.20065","article-title":"Hyperuricemia and coronary heart disease: a systematic review and meta-analysis","volume":"62","author":"Kim","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0033","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2013.08.023","article-title":"Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies","volume":"231","author":"Zhao","year":"2013","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0034","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.STR.0000221716.55088.d4","article-title":"Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study","volume":"37","author":"Bos","year":"2006","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.028_bib0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40292-023-00602-4","volume":"30","author":"Maloberti","year":"2023","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"10","key":"10.1016\/j.ejim.2025.07.028_bib0036","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029633","article-title":"Association of normal serum uric acid level and cardiovascular disease in people without risk factors for cardiac diseases in China","volume":"12","author":"Tian","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.028_bib0037","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1681\/ASN.2014070660","article-title":"Uric acid and cardiovascular events: a mendelian randomization study","volume":"26","author":"Kleber","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.028_bib0038","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s11239-021-02453-z","article-title":"Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis","volume":"52","author":"Yang","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.028_bib0039","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000512178","article-title":"Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients","volume":"30","author":"Cicero","year":"2021","journal-title":"Med Princ Pract"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.028_bib0040","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s11886-024-02138-y","article-title":"Cardiovascular outcomes of Uric acid lowering medications: a meta-analysis","volume":"26","author":"Jamil","year":"2024","journal-title":"Curr Cardiol Rep"},{"issue":"8","key":"10.1016\/j.ejim.2025.07.028_bib0041","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10654-024-01138-0","article-title":"A phenome-wide association and factorial mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes","volume":"39","author":"Wang","year":"2024","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2025.104025","article-title":"Serum uric acid fluctuations and cardiovascular outcomes in hospitalized acute heart failure patients","volume":"35","author":"Liao","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0043","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-76970-1","article-title":"Association of serum uric acid with all-cause and cardiovascular mortality in cardiovascular disease patients","volume":"14","author":"Lv","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.028_bib0044","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","article-title":"Safety and tolerability of available urate-lowering drugs: a critical review","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.028_bib0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2337\/dc22-1339","article-title":"Association of serum uric acid with all-cause and cardiovascular mortality in diabetes","volume":"46","author":"Li","year":"2023","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.028_bib0046","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","article-title":"Association of uric acid with change in kidney function in healthy normotensive individuals","volume":"56","author":"Bellomo","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.ejim.2025.07.028_bib0047","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1093\/ndt\/gfq740","article-title":"Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study","volume":"26","author":"Ben-Dov","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.028_bib0048","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1681\/ASN.2004030208","article-title":"Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study","volume":"16","author":"Domrongkitchaiporn","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.028_bib0049","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1093\/ndt\/gfu256","article-title":"A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population","volume":"29","author":"Kamei","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2025.07.028_bib0050","doi-asserted-by":"crossref","unstructured":"Sedaghat S., Hoorn E.J., van Rooij F.J., Hofman A., Franco O.H., Witteman J.C., Dehghan A. Serum uric acid and chronic kidney disease: the role of hypertension. PLoS One. 2013 Nov 12;8(11):e76827. doi: 10.1371\/journal.pone.0076827.","DOI":"10.1371\/journal.pone.0076827"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0051","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1681\/ASN.2007101075","article-title":"Uric acid and incident kidney disease in the community","volume":"19","author":"Weiner","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0052","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2337\/dc10-0227","article-title":"High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up","volume":"33","author":"Ficociello","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0053","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/dc11-1346","article-title":"Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function","volume":"35","author":"Zoppini","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.028_bib0054","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","article-title":"Relationship of uric acid with progression of kidney disease","volume":"50","author":"Chonchol","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.028_bib0055","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","article-title":"Risk factors for end-stage renal disease: 25-year follow-up","volume":"169","author":"Hsu","year":"2009","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.028_bib0056","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":"Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.ejim.2025.07.028_bib0057","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/j.1600-6143.2011.03613.x","article-title":"Association of serum uric acid with graft survival after kidney transplantation: a time-varying analysis","volume":"11","author":"Haririan","year":"2011","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.028_bib0058","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/TP.0b013e3181c73c18","article-title":"The independent association between serum uric acid and graft outcomes after kidney transplantation","volume":"89","author":"Haririan","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.ejim.2025.07.028_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","article-title":"Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease","volume":"80","author":"Borghi","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.028_bib0060","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.amjhyper.2007.08.010","article-title":"Mild hyperuricemia and subclinical renal damage in untreated primary hypertension","volume":"20","author":"Viazzi","year":"2007","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0061","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.3390\/ijms23063188","article-title":"Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment","volume":"23","author":"Gherghina","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0062","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/eurheartj\/ehq473","article-title":"chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data","volume":"32","author":"Filippatos","year":"2011","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.028_bib0063","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.amjcard.2014.09.008","volume":"114","author":"Vaduganathan","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2025.07.028_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132906","article-title":"Italian Network on Heart Failure (IN-HF) investigators. Serum uric acid, renal function and prognosis in patients with chronic heart failure and reduced ejection fraction. Insights from the Italian Network on Heart Failure","volume":"421","author":"Minneci","year":"2025","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.028_bib0065","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.numecd.2020.11.017","article-title":"Elevated serum uric acid and risk of cardiovascular or all-cause mortality in maintenance hemodialysis patients: a meta-analysis","volume":"31","author":"Wang","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.028_bib0066","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1744-9987.14252","article-title":"Lower time-averaged serum uric acid was associated with increased mortality in peritoneal dialysis patients","volume":"29","author":"Li","year":"2025","journal-title":"Ther Apher Dial"},{"issue":"23","key":"10.1016\/j.ejim.2025.07.028_bib0067","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023054","article-title":"Metabolic factors mediate the association between serum uric acid to serum creatinine ratio and cardiovascular disease","volume":"10","author":"Wang","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0068","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/HJH.0000000000003319","article-title":"Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Serum uric acid \/serum creatinine ratio as a predictor of cardiovascular events. Detection of prognostic cardiovascular cut-off values","volume":"41","author":"Casiglia","year":"2023","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0069","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/metabo15010011","article-title":"Asymptomatic hyperuricemia and the kidney: lessons from the URRAH Study","volume":"15","author":"Barnini","year":"2025","journal-title":"Metabolites"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.028_bib0070","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.ejim.2025.07.028_bib0071","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/ndt\/gft029","article-title":"Uric acid and chronic kidney disease: which is chasing which?","volume":"28","author":"Johnson","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0072","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1161\/01.HYP.0000072820.07472.3B","article-title":"Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2","volume":"41","author":"Kanellis","year":"2003","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0073","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.semnephrol.2020.12.004","article-title":"Hyperuricemia in Kidney disease: a major risk factor for cardiovascular events, vascular calcification, and renal damage","volume":"40","author":"Ejaz","year":"2020","journal-title":"Semin Nephrol"},{"issue":"8","key":"10.1016\/j.ejim.2025.07.028_bib0074","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12882-022-02850-3","article-title":"Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials","volume":"23","author":"Sapankaew","year":"2022","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0076","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12882-024-03491-4","article-title":"Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis","volume":"25","author":"Luo","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ejim.2025.07.028_bib0077","doi-asserted-by":"crossref","unstructured":"Doria A., Galecki A.T., Spino C., Pop-Busui R., Cherney D.Z., Lingvay I., Parsa A., Rossing P., Sigal R.J., Afkarian M., Aronson R., Caramori M.L., Crandall J.P., de Boer I.H., Elliott T.G., Goldfine A.B., Haw J.S., Hirsch I.B., Karger A.B., Maahs D.M., McGill J.B., Molitch M.E., Perkins B.A., Polsky S., Pragnell M., Robiner W.N., Rosas S.E., Senior P., Tuttle K.R., Umpierrez G.E., Wallia A., Weinstock R.S., Wu C., Mauer M.; P.E.R.L. Study Group. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020 Jun 25;382(26):2493\u2013503. doi: 10.1056\/NEJMoa1916624.","DOI":"10.1056\/NEJMoa1916624"},{"issue":"26","key":"10.1016\/j.ejim.2025.07.028_bib0078","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"CKD-FIX study investigators. Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0079","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/ckj\/sfaa236","article-title":"The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality","volume":"13","author":"Gonzalez-Martin","year":"2020","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.028_bib0080","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040626","article-title":"Asymptomatic hyperuricemia promotes recovery from ischemic organ injury by modulating the phenotype of macrophages","volume":"11","author":"Gnemmi","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejim.2025.07.028_bib0081","doi-asserted-by":"crossref","unstructured":"Cicero A.F.G., Fogacci F., Kuwabara M., Borghi C. Therapeutic strategies for the treatment of chronic hyperuricemia: an evidence-based update. Medicina (Kaunas). 2021 Jan 10;57(1):58. doi: 10.3390\/medicina57010058.","DOI":"10.3390\/medicina57010058"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0082","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamainternmed.2024.6212","article-title":"Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease","volume":"185","author":"Wang","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0083","article-title":"Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3-5 patients with asymptomatic hyperuricemia: a network meta-analysis","volume":"47","author":"Chen","year":"2025","journal-title":"Ren fail"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0084","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2332956","article-title":"Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials","volume":"56","author":"Yang","year":"2024","journal-title":"Ann Med"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.028_bib0085","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.kint.2024.05.033","article-title":"Controversies and practical management of patients with gout and chronic kidney disease","volume":"106","author":"Johnson","year":"2024","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.ejim.2025.07.028_bib0086","doi-asserted-by":"crossref","first-page":"e7180","DOI":"10.1002\/cam4.7180","article-title":"Impact of hyperuricemia and chronic kidney disease on the prevalence and mortality of cardiovascular disease in cancer survivors","volume":"13","author":"Chen","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejim.2025.07.028_bib0087","doi-asserted-by":"crossref","DOI":"10.1111\/1744-9987.70000","article-title":"The role of hyperuricemia in the progression of end-stage kidney disease and its molecular prospective in inflammation and cardiovascular diseases: a general review","author":"Waheed","year":"2025","journal-title":"Ther Apher Dial"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.028_bib0088","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/MS9.0000000000001731","article-title":"Prevalence and clinical characteristics of hyperuricemia among patients with chronic kidney disease under haemodialysis in a tertiary care center: a cross-sectional study","volume":"86","author":"Bhattarai","year":"2024","journal-title":"Ann Med Surg"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.028_bib0089","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/s41588-024-01921-5","article-title":"A genome-wide association analysis reveals new pathogenic pathways in gout","volume":"56","author":"Major","year":"2024","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12872-016-0379-z","article-title":"Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies","volume":"16","author":"Zuo","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0091","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2013.08.023","article-title":"Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies","volume":"231","author":"Zhao","year":"2013","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.028_bib0092","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/HYPERTENSIONAHA.119.13643","article-title":"Identification of the Uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years","volume":"75","author":"Virdis","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2025.07.028_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1306026","article-title":"Association between hyperuricemia and long-term mortality in patients with hypertension: results from the NHANES 2001-2018","volume":"11","author":"Yin","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.028_bib0094","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0302386","article-title":"Association between hyperuricemia and the risk of mortality in patients with osteoarthritis: a study based on the National Health and Nutrition Examination Survey database","volume":"19","author":"Hao","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2025.07.028_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100371","article-title":"Higher serum uric acid levels and risk of all-cause mortality in general population: a systematic review and meta-analysis","volume":"26","author":"Rabbani","year":"2025","journal-title":"Metabol Open"},{"key":"10.1016\/j.ejim.2025.07.028_bib0096","article-title":"Joint association of hyperuricemia and chronic kidney disease with mortality in patients with chronic heart failure","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.028_bib0097","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1536\/ihj.24-220","article-title":"Relationship between Uric acid and all-cause and cardiovascular mortality in individuals with hypertension","volume":"66","author":"Gan","year":"2025","journal-title":"Int Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0098","doi-asserted-by":"crossref","first-page":"128","DOI":"10.46497\/ArchRheumatol.2025.10808","article-title":"Hyperuricemia and the risk of stroke incidence and mortality: a systematic review and meta-analysis","volume":"40","author":"Jiang","year":"2025","journal-title":"Arch Rheumatol"},{"issue":"9","key":"10.1016\/j.ejim.2025.07.028_bib0099","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.numecd.2023.05.023","article-title":"Concurrence of hyperinsulinemia and hyperuricemia significantly augmented all-cause mortality","volume":"33","author":"Acevedo-Fern\u00e1ndez","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2025.07.028_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1286206","article-title":"Interaction between anemia and hyperuricemia in the risk of all-cause mortality in patients with chronic kidney disease","volume":"15","author":"Lu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.028_bib0101","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/HJH.0000000000002287","article-title":"Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: the URRAH (Uric Acid Right for Heart Health) study","volume":"38","author":"Casiglia","year":"2020","journal-title":"J Hypertens"},{"issue":"7","key":"10.1016\/j.ejim.2025.07.028_bib0102","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.24612","article-title":"Hyperuricemia and risk of stroke: a systematic review and metaanalysis","volume":"61","author":"Kim","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0103","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75508-9","article-title":"Effect of high sensitivity C-reactive protein on uric acid-related cardiometabolic risk in patients with coronary artery disease-a large multicenter prospective study","volume":"14","author":"Song","year":"2024","journal-title":"Sci Rep"},{"issue":"2890","key":"10.1016\/j.ejim.2025.07.028_bib0104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(02)46030-8","article-title":"On chronic bright\u2019s disease, and its essential symptoms","volume":"113","author":"Mahomed","year":"1879","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0105","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","article-title":"Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism","volume":"282","author":"Mazzali","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"issue":"10","key":"10.1016\/j.ejim.2025.07.028_bib0106","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41440-023-01331-w","article-title":"Overnight changes in uric acid, xanthine oxidoreductase and oxidative stress levels and their relationships with sleep-disordered breathing in patients with coronary artery disease","volume":"46","author":"Shimizu","year":"2023","journal-title":"Hypertens Res"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.028_bib0107","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1067\/mhj.2001.114367","article-title":"Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance","volume":"141","author":"Doehner","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2025.07.028_bib0108","doi-asserted-by":"crossref","DOI":"10.1161\/STROKEAHA.123.042708","article-title":"PhD cumulative serum uric acid exposure and its time course with the risk of incident stroke","volume":"54","author":"Tian","year":"2023","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.028_bib0109","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2013.11.051","article-title":"Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies","volume":"232","author":"Li","year":"2014","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.028_bib0110","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/jch.12855","article-title":"Hyperuricemia and the prognosis of hypertensive patients: a systematic review and meta-analysis","volume":"18","author":"Qin","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"13","key":"10.1016\/j.ejim.2025.07.028_bib0111","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020180","article-title":"Cumulative serum uric acid and its time course are associated with risk of myocardial infarction and all-cause mortality","volume":"10","author":"Tian","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.ejim.2025.07.028_bib0112","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014525","article-title":"Prognostic value of serum uric acid in patients with acute heart failure: a meta-analysis","volume":"98","author":"Huang","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.ejim.2025.07.028_bib0113","doi-asserted-by":"crossref","unstructured":"Muiesan M.L., Salvetti M., Virdis A., Masi S., Casiglia E., Tikhonoff V., et al. Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. J Hypertens. 2021 Jan;39(1):62\u201369.","DOI":"10.1097\/HJH.0000000000002589"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.028_bib0114","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13074","article-title":"Prognostic value of hyperuricemia in patients with acute coronary syndrome: a meta-analysis","volume":"49","author":"He","year":"2019","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejim.2025.07.028_bib0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2016.10.006","article-title":"Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: a meta-analysis","volume":"254","author":"Wang","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0116","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12882-018-1143-7","article-title":"Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis","volume":"20","author":"Luo","year":"2019","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.028_bib0117","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2047487313514895","article-title":"Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis","volume":"22","author":"Clarson","year":"2015","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"10.1016\/j.ejim.2025.07.028_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2019.07.006","article-title":"Serum uric acid as a risk factor of all-cause mortality and cardiovascular events among type 2 diabetes population: meta-analysis of correlational evidence","volume":"33","author":"Shao","year":"2019","journal-title":"J Diabet Complications"},{"key":"10.1016\/j.ejim.2025.07.028_bib0119","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2337\/dc22-1339","article-title":"Association of serum uric acid with all-cause and cardiovascular mortality in diabetes","volume":"46","author":"Li","year":"2023","journal-title":"Diab Care"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0120","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American College of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.028_bib0121","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41401-025-01476-z","article-title":"Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies","volume":"46","author":"Zhao","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ejim.2025.07.028_bib0122","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1190069","article-title":"Gout and hyperuricaemia: modifiable cardiovascular risk factors?","volume":"10","author":"Burnier","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10.1016\/j.ejim.2025.07.028_bib0123","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/jpm13091409","article-title":"The role of uric acid in Human health: insights from the uricase gene","volume":"13","author":"Roman","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.ejim.2025.07.028_bib0124","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmed.2018.00160","article-title":"Physiology of hyperuricemia and urate-lowering treatments","volume":"5","author":"Benn","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.028_bib0125","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1523-1755.2005.00273.x","article-title":"Hyperuricemia induces endothelial dysfunction","volume":"67","author":"Khosla","year":"2005","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.028_bib0126","doi-asserted-by":"crossref","first-page":"54","DOI":"10.15420\/ecr.2016:4:2","article-title":"Uric Acid and cardiovascular Disease: an update","volume":"11","author":"Muiesan","year":"2016","journal-title":"Eur Cardiol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T07:16:53Z","timestamp":1764659813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525003127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":127,"alternative-id":["S0953620525003127"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.07.028","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crystal clear \u2013 part I: The role of uric acid in cardiorenal disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106432"}}